PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of a PRC2 (Polycomb Repressive Complex 2) inhibitor compound for cancer treatment. The application, filed September 13, 2023 (Application No. 19110340), covers the physical forms of the compound, pharmaceutical compositions containing these forms, and methods of treating cancer subjects. The CPC classification is C07D 487/04 (heterocyclic compounds - organic chemistry). Inventors are Mohammad AL-SAYAH and Robert Ronald MILBURN.

Pharmaceutical and biotechnology companies developing PRC2 inhibitors or engaged in cancer therapeutics research should review this application for potential freedom-to-operate concerns or licensing opportunities. Third parties may submit prior art references during the examination period. Patent prosecution typically continues for 2-3 years or longer before the application is granted or rejected. No immediate compliance obligations are created by this publication.